TCRT

+ Watchlist + Portfolio

Alaunos Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.88
52-Week Range: $1.67 – $4.59
Market Cap: $4.57M
P/E (TTM): —
EPS (TTM): -1.68
Dividend Yield: —

Advanced Metrics

Price/Book: 3.32
PEG Ratio: 0.58
Return on Equity: -350.30%
Return on Assets: -129.43%
Gross Margin: 0.00%
Operating Margin: -138166.67%
Profit Margin: 0.00%
Current Ratio: 1.63
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-2.14M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.32M

TCRT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.92M	$5.00K	$10.00K	$5.00K
Research & Development	$25.02M	$16.28M	$362.00K	$1.36M
Selling, General & Admin	$13.14M	$12.22M	$4.46M	$2.87M
Operating Expenses	$38.16M	$28.50M	$4.82M	$4.23M
Operating Income	-$35.24M	-$28.49M	-$4.81M	-$4.22M
EBITDA	-$31.82M	-$30.90M	-$4.81M	-$4.22M
Pretax Income	-$37.73M	-$35.14M	-$4.68M	-$4.18M
Net Income	-$37.73M	-$35.14M	-$4.68M	-$4.18M
Diluted EPS	-25.50	-21.97	-2.92	-2.20
Diluted Shares	1.45M	1.60M	1.60M	1.95M

TCRT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$39.06M	$6.06M	$1.09M	$1.39M
Receivables	$4.00K	$1.00K	$5.00K	$3.00K
Current Assets	$53.80M	$8.26M	$2.75M	$1.99M
Total Assets	$64.94M	$8.26M	$2.75M	$2.97M
Current Liabilities	$24.17M	$1.96M	$692.00K	$813.00K
Total Debt	$19.51M	$0.00	—	—
Total Liabilities	$26.38M	$1.96M	$692.00K	$813.00K
Retained Earnings	-$880.63M	-$915.77M	-$920.45M	-$924.62M
Shareholders' Equity	$38.55M	$6.31M	$2.06M	$2.15M
Working Capital	$29.63M	$6.30M	$2.06M	$1.18M

TCRT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.23M	-$30.14M	-$4.97M	-$2.87M
Capital Expenditure	-$216.00K	-$197.00K	—	-$98.00K
Free Cash Flow	-$29.45M	-$30.34M	-$4.97M	-$2.97M
Depreciation & Amortisation	$2.76M	$2.31M	$2.00K	$7.00K
Stock-Based Compensation	$3.53M	$2.80M	$435.00K	$414.00K
Investing Cash Flow	-$193.00K	$1.35M	$0.00	-$98.00K
Financing Cash Flow	$6.37M	-$18.14M	$0.00	$3.26M
Share Repurchases	-$45.00K	$0.00	—	—
Net Change in Cash	-$23.06M	-$46.93M	-$4.97M	$294.00K

TCRT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.00K	$0.00	$0.00	$3.00K	$0.00
Research & Development	$347.00K	$185.00K	$469.00K	$361.00K	$427.00K
Selling, General & Admin	$747.00K	$854.00K	$718.00K	$549.00K	$585.00K
Operating Expenses	$1.09M	$1.04M	$1.19M	$910.00K	$1.01M
Operating Income	-$1.09M	-$1.04M	-$1.19M	-$907.00K	-$1.01M
EBITDA	-$1.09M	-$1.04M	-$1.19M	-$900.00K	-$1.00M
Pretax Income	-$1.07M	-$1.05M	-$1.16M	-$893.00K	-$1.01M
Net Income	-$1.07M	-$1.05M	-$1.16M	-$893.00K	-$1.01M
Diluted EPS	-0.67	-0.63	-0.55	—	-0.59
Diluted Shares	1.60M	1.68M	2.18M	—	1.95M

TCRT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$319.00K	$2.88M	$1.94M	$1.39M	$354.00K
Receivables	$2.00K	$2.00K	$0.00	$3.00K	$0.00
Current Assets	$1.07M	$3.74M	$2.69M	$1.99M	$970.00K
Total Assets	$2.12M	$4.74M	$3.72M	$2.97M	$1.88M
Current Liabilities	$1.06M	$1.07M	$921.00K	$813.00K	$595.00K
Total Liabilities	$1.06M	$1.07M	$921.00K	$813.00K	$595.00K
Retained Earnings	-$921.52M	-$922.57M	-$923.73M	-$924.62M	-$925.63M
Shareholders' Equity	$1.06M	$3.66M	$2.80M	$2.15M	$1.29M
Working Capital	$5.00K	$2.66M	$1.76M	$1.18M	$375.00K

TCRT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$772.00K	-$701.00K	-$844.00K	-$552.00K	-$1.03M
Capital Expenditure	—	—	—	-$1.00K	—
Free Cash Flow	-$772.00K	-$701.00K	-$941.00K	-$553.00K	-$1.03M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$7.00K	$8.00K
Stock-Based Compensation	$68.00K	$184.00K	$127.00K	$35.00K	$56.00K
Investing Cash Flow	—	—	—	-$1.00K	—
Financing Cash Flow	—	—	$0.00	$0.00	—
Net Change in Cash	-$772.00K	$2.56M	-$941.00K	-$553.00K	-$1.03M

Market Snapshot

About

Alaunos Therapeutics, Inc. is a clinical-stage cell therapy company focused on developing adoptive T cell receptor (TCR) therapies for the treatment of solid tumors. The company engineers patient T cells to recognize and attack cancer cells by targeting specific tumor-associated antigens. Alaunos is advancing multiple TCR programs for various cancer indications.